You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR GLIADEL

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for GLIADEL

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003463 ↗	Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas	Completed	National Cancer Institute (NCI)	Phase 1	1998-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
NCT00003463 ↗	Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas	Completed	Duke University	Phase 1	1998-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
NCT00003467 ↗	Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma	Completed	National Cancer Institute (NCI)	Phase 2	1998-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
NCT00003467 ↗	Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma	Completed	Duke University	Phase 2	1998-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
NCT00003876 ↗	Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma	Completed	Barrett Cancer Center	Phase 1	1999-04-01	RATIONALE: Internal radiation uses high-energy radiation to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining internal radiation therapy with chemotherapy implants may kill remaining tumor cells following surgery. PURPOSE: Phase I trial to study the effectiveness of internal radiation therapy plus carmustine implants in treating patients who have recurrent or refractory malignant glioma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for GLIADEL

Condition Name

Chart
Table

Condition Name for GLIADEL
Intervention	Trials
Glioblastoma Multiforme	8
Brain and Central Nervous System Tumors	8
Glioblastoma	5
Recurrent Small Lymphocytic Lymphoma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for GLIADEL
Intervention	Trials
Glioblastoma	17
Glioma	16
Lymphoma	13
Lymphoma, Non-Hodgkin	11
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for GLIADEL

Trials by Country

Map
Table

Trials by Country for GLIADEL
Location	Trials
United States	170
Canada	10
United Kingdom	4
Germany	3
Israel	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for GLIADEL
Location	Trials
North Carolina	15
Washington	12
Texas	11
Ohio	9
Pennsylvania	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for GLIADEL

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for GLIADEL
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	21
Phase 1/Phase 2	9
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for GLIADEL
Clinical Trial Phase	Trials
Completed	23
Terminated	7
Unknown status	7
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GLIADEL

Sponsor Name

Chart
Table

Sponsor Name for GLIADEL
Sponsor	Trials
National Cancer Institute (NCI)	25
Fred Hutchinson Cancer Research Center	8
Eisai Inc.	6
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for GLIADEL
Sponsor	Trials
Other	36
NIH	26
Industry	17
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.